New Clathrin-Based Nanoplatforms for Magnetic Resonance Imaging by Vitaliano, Franco et al.
 
New Clathrin-Based Nanoplatforms for Magnetic Resonance
Imaging
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Vitaliano, Gordana D., Franco Vitaliano, Jose D. Rios, Perry F.
Renshaw, and Martin H. Teicher. 2012. New clathrin-based
nanoplatforms for magnetic resonance imaging. PLoS ONE 7(5):
e35821.
Published Version doi:10.1371/journal.pone.0035821
Accessed February 19, 2015 10:33:40 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10364592
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAANew Clathrin-Based Nanoplatforms for Magnetic
Resonance Imaging
Gordana D. Vitaliano
1*, Franco Vitaliano
2, Jose D. Rios
1, Perry F. Renshaw
3, Martin H. Teicher
1
1Laboratory of Developmental Psychopharmacology, Brain Imaging Center, Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts,
United States of America, 2VXM, Boston, Massachusetts, United States of America, 3The Brain Institute, University of Utah School of Medicine, Salt Lake City, Utah,
United States of America
Abstract
Background: Magnetic Resonance Imaging (MRI) has high spatial resolution, but low sensitivity for visualization of
molecular targets in the central nervous system (CNS). Our goal was to develop a new MRI method with the potential for
non-invasive molecular brain imaging. We herein introduce new bio-nanotechnology approaches for designing CNS
contrast media based on the ubiquitous clathrin cell protein.
Methodology/Principal Findings: The first approach utilizes three-legged clathrin triskelia modified to carry 81 gadolinium
chelates. The second approach uses clathrin cages self-assembled from triskelia and designed to carry 432 gadolinium
chelates. Clathrin triskelia and cages were characterized by size, structure, protein concentration, and chelate and
gadolinium contents. Relaxivity was evaluated at 0.47 T. A series of studies were conducted to ascertain whether
fluorescent-tagged clathrin nanoplatforms could cross the blood brain barriers (BBB) unaided following intranasal,
intravenous, and intraperitoneal routes of administration. Clathrin nanoparticles can be constituted as triskelia (18.5 nm in
size), and as cages assembled from them (55 nm). The mean chelate: clathrin heavy chain molar ratio was 27.0464.8: 1 for
triskelia, and 4.261.04: 1 for cages. Triskelia had ionic relaxivity of 16 mM
21s
21, and molecular relaxivity of 1,166 mM
21s
21,
while cages had ionic relaxivity of 81 mM
21s
21 and molecular relaxivity of 31,512 mM
21s
21. Thus, cages exhibited 20 times
higher ionic relaxivity and 8,000-fold greater molecular relaxivity than gadopentetate dimeglumine. Clathrin nanoplatforms
modified with fluorescent tags were able to cross or bypass the BBB without enhancements following intravenous,
intraperitoneal and intranasal administration in rats.
Conclusions/Significance: Use of clathrin triskelia and cages as carriers of CNS contrast media represents a new approach.
This new biocompatible protein-based nanotechnology demonstrated suitable physicochemical properties to warrant
further in vivo imaging and drug delivery studies. Significantly, both nanotransporters crossed and/or bypassed the BBB
without enhancers. Thus, clathrin nanoplatforms could be an appealing alternative to existing CNS bio-nanotechnologies.
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Introduction
A major focus in contrast agent research has been on molecular-
level imaging, encompassing the study of receptors, transporters,
enzymes, genes and intracellular processes. Positron emission
tomography (PET) is among the most sensitive molecular imaging
techniques, especially for central nervous system (CNS) applica-
tions. However, PET is limited by low spatial resolution, the need
for some radioactive tracers to be produced locally, and limited
availability of these tools and techniques.
Magnetic Resonance Imaging (MRI) is a widely used noninva-
sive visualization technique with high spatial resolution, but low
sensitivity for visualization of molecular targets [1]. To improve
MRI sensitivity for brain imaging, several contrast agent (CA)
nano-delivery strategies have been designed [2,3,4,5]. For
example, by attaching paramagnetic (e.g., gadolinium) or super-
paramagnetic (e.g., iron oxide) agents to macromolecules relaxivity
of MRI contrast agents can be significantly improved providing
useful tracers [6,7,8]. Attached antibodies or ligands can also
provide selective targeting [8,9]. Also, dual imaging nanoplatforms
detectable both by MRI and fluorescent microscopy can be used
to delineate small primary tumors and metastases [10].
Over the past 30 years, various protein-based nanoplatforms,
dendrimers, nanogels and other polymeric nanoparticles, lipo-
somes, micelles, solid-lipid nanoparticles and Fullerenes, to name
some, have been developed that show promise for imaging and
also for delivery of different CNS therapies
[11,12,13,14,15,16,17,18]. Each nanotechnology has its own
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nanoplatforms has also been a problem, but can be improved
using several strategies [8]. However, each strategy poses its own
risks [8].
Protein based nanoplatforms have shown great promise as CA
carriers. For example, one of the first macromolecular CA,
albumin-Gd-DTPA, exhibited molecular relaxivity of
273 mM
21s
21, and ionic relaxivity of 14 mM
21s
21 [21].
Although widely used in preclinical studies, the covalently bound
albumin-Gd-DTPA complexes have not been applied clinically,
because of their slow clearance. However, the most recent Gd-
based blood pool agents (e.g., MS-325, Gd-BOPTA) non-
covalently attach to human serum albumin (HSA), which
significantly improves their relaxivity and their pharmacokinetic
properties [22,23,24]. But, they cannot cross an intact BBB. Some
proteins (e.g., antibodies) have excellent targeting abilities, but
limited loading efficacy. Others, like viruses, have ultra-high
relaxivity, but are highly immunogenic. Finding an appropriate
nontoxic, non-immunogenic, efficient CA carrier that can also
cross the BBB has been a real challenge.
Several transport mechanisms are known to be involved in
uptake of elements by the brain across the BBB [5,25,26]. A
noninvasive nano-delivery mechanism to the CNS would be highly
desirable in clinical imaging, and for nano-medicine in general.
Invasive and noninvasive methods have been developed to deliver
various types of elements across the BBB, but their clinical
effectiveness has not been shown to be better than existing
therapeutic methods [2]. New BBB-passing technologies include:
lipidization, chemical or mechanical alteration of the BBB,
convection-enhanced delivery (CED), and active and/or facilitated
transport.
With respect to BBB passing of CA nanoparticles, various
technologies and methods can be used with varying degrees of
success. These typically entail nanoparticle functionalization with
different types of molecules, including: surfactants (e.g., polysor-
bate 80), anti-transferrin or insulin receptor antibodies, single
domain antibodies, and different peptide vectors (e.g., SynB
vectors, Penetratin and TAT) [27]. On the other hand, intranasal
delivery provides a direct transport pathway for nanoparticles into
the brain by bypassing the BBB, which also may be useful in
imaging [28].
A new method has been developed for non-invasive delivery of
CA into the CNS, which further has the potential to enable high-
resolution imaging. This method utilizes clathrin protein, and in
particular, uses clathrin triskelia (CTs) [29]. These three-legged
proteins are found in human, animal, plant, and fungal cells
[30,31,32]. Clathrin triskelia can self-assemble into clathrin cages
(CCs) ranging from 30 nm to 100 nm in size. CCs can encapsulate
lipid vesicles [33], resulting in clathrin-coated vesicles (CCVs).
These are the primary intracellular delivery vehicles responsible
for receptor-mediated endocytosis at the plasma membrane, and
for sorting of proteins at the trans-Golgi network [30,31,32].
Clathrin-mediated endocytosis is important for efficacy of anti-
receptor monoclonal antibody-based tumor therapy, and for
susceptibility to double-strained RNA-mediated gene silencing
[34]. CCVs have a native ability to simultaneously carry different
types of elements, such as: antibodies, hormones, growth factors,
and neurotransmitters [30]. The rigid clathrin protein cage
stabilizes its cargo and environmentally sequesters the vesicle
and its contents. The clathrin lattice is also durable, is about 100-
fold stiffer than the typical liposome [35] and is resistant to pH
changes and trypsin digestion [36]. It also has multiple groups that
can easily be modified (e.g., lysine, cysteine). These manifold
qualities make clathrin structures suitable for study as CA nano-
transporters [29]. Clathrin is shown to be active outside cells,
natively crosses cell membranes, moves between neurons [37], and
is active at the BBB [38,39], which further suggest new CNS
imaging capabilities. Accordingly, we set out to find whether
clathrin could be used in MRI to improve relaxivity of contrast
agents for CNS imaging.
In this study, the goal was to develop nontoxic, self-assembled,
clathrin-based nanoplatforms for imaging within the CNS. The
first objective was to chelate clathrin protein for MRI, and
determine chelate ligand 2-(4-Isothiocyanatobenzyl)-diethylene-
triamine-pentaacetic acid (DTPA-ITC) to clathrin protein molar
ratio (L/P). The second objective was to attach a metal ion often
used in imaging (e.g., Gadolinium), and determine T1 relaxivity
for MRI applications. The final objective was to attach a
fluorescent tag (e.g., fluorescein-isothiocyanate (FITC) or rhoda-
mine), and, by using fluorescent imaging, test if the clathrin
nanoplatforms could cross or bypass the BBB in rats.
Methods
Ethics Statement
Experiments were conducted in accordance with National
Institutes of Health 1996 Guide for the Care and Useof Laboratory
Animals and approved by McLean Hospital’s Institutional Animal
Care and Use Committee (Protocol #07-6/2-21).
Animals
Male Sprague Dawley (SD) rats (250 g–300 g) (Charles River,
Boston, MA) were housed with ad libitum food and water in
constant temperature and humidity conditions on a 12 hr. light/
dark cycle.
Reagents
Unless otherwise indicated, all chemicals were from Sigma-
Aldrich, and included: sodium azide, gadolinium chloride, yttrium
chloride, arsenazo III, EDTA, Isocyanatobenzyl-DTPA (Macro-
cyclics, Dallas, TX), Maleimide-poly-(ethylene-glycol)-N-hydroxy-
succinimide (JenKen Tech., Allen, TX), rhodamine 110, FITC
Labeling Kit (Pierce, Rockford, IL).
The compositions of the buffers were as follows: a) triskelia
‘‘dissociation buffer’’, Tris (tris(hydroxymethyl)-aminomethane)
buffer, 0.5 M Tris-HCl, 3 mM dithiothreitol (DTT), the pH=7;
b) triskelia ‘‘chelation buffer’’, HEPES [N-(2-Hydroxyethyl)
piperazine-N’-ethanesulfonic acid] buffer, 0.1 M HEPES, the
pH=8.5; c) cages ‘‘assembly buffer’’, MES [2-(N-morpholino)
ethanesulfonicacid] buffer, 50 mM MES Na, 100 mM NaCl,
2 mM DTT, the pH=6.5; d) cages ‘‘storage buffer’’, MES buffer,
20 mM MES Na, 2 mM DTT, the pH=6.2; e) phosphate buffer,
50 mM KH2P04, the pH (6.7–8.3) was adjusted with the addition
of 0.1 M NaOH; e) 0.1 M ammonium acetate buffer, the pH (5.5–
6) and f) 0.15 M sodium acetate buffer, the pH=4.
Protein Isolation
Clathrin-coated vesicles were isolated from fresh rat livers and
brains, and clathrin triskelia and adaptor proteins isolated using
standard methods [33]. Clathrin triskelia (5 mg/ml) in 0.5 M Tris
buffer (pH 7) was dialyzed against at least a 500-fold volume
excess of 0.1 M HEPES buffer (pH 8.5) containing 50 mM EDTA
for 8 hours at 4uC and protein concentration determined by
Bradford protein assay (Bio-Rad, Hercules, CA).
Nanoplatforms for Magnetic Resonance Imaging
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Triskelia. A 120-fold molar excess of 2-(4-
Isothiocyanatobenzyl)-diethylene-triamine-pentaacetic acid
(DTPA-ITC, Macrocyclics, Dallas, TX) was added to triskelia
(5 mg/ml) in 0.1 M HEPES buffer (pH 8.5) and incubated for
8 hours at 4uC. Chelator was conjugated to protein through lysine
residues [40]. Protein was then washed 6 times in 0.1 M
ammonium acetate (pH 6) by using Amicon-Ultra-4 with
100 kDa MWCO (Millipore, Billerica, MA) according to the
published method [41]. Protein concentration was determined by
Bradford protein assay (Bio-Rad, Hercules, CA).
Cages. A 15-fold molar excess of DTPA-ITC was added to
clathrin triskelia (5 mg/ml) in 0.1 M HEPES buffer (pH 8.5) and
incubated for 8 hours at 4uC. Clathrin cages were assembled by
mixing modified clathrin triskelia and AP-2 proteins at a ratio of
3:1 (v/v) according to the standard method [42]. The mixture was
dialyzed against MES buffer (50 mM MES Na, pH 6.5, 100 mM
NaCl, 2 mM DTT) two times for 12 hours at 4uC, and any
unconjugated chelator was separated from nanoplatforms. The
relatively high NaCl concentration in the MES buffer was used to
facilitate formation of D6 barrel CCs [42]. Aggregated protein was
removed by centrifugation in an Eppendorf centrifuge at
15,000 rpm at 4uC for 10 min. Assembled cages were separated
from unassembled triskelia by high-speed centrifugation at
60,000 rpm in a TLA-100.4 rotor (Beckman Coulter, US) at
4uC for 12 min, and then resuspended in MES buffer (20 mM
MES Na, pH 6.2, 2 mM DTT) to a final concentration of
2.28 mg/ml. Protein concentration was determined by Bradford
protein assay (Bio-Rad, Hercules, CA).
Arsenazo assay. Ligand (DTPA-ITC) to protein molar ratio
was determined by using a spectrophotometric method [43] that
was based on reaction between DTPA-ITC-protein conjugate and
yttrium (Y
3+) complex of arsenazo III. Arsenazo III is a highly
sensitive colorimetric reagent for yttrium and other metal ions. A
500 ml stock solution of the Y
3+ -arsenazo III complex contained:
5 mM arsenazo III, 1.6 mMY
3+ and 0.15 M sodium acetate buffer
(pH 4). From 10 to 60 mL of 0.123 mM DTPA-ITC were added
serially to the cuvette that contained Y
3+ -arsenazo III complex.
Absorbance values were measured at 652 nm by using the
Spectronic GENESYS 10 Bio spectrophotometer (Thermo
Electron Corp., Madison, WI) and a calibration plot
constructed. Then, from 20 to 80 mL of DTPA-ITC-protein
conjugate were added to the Y
3+ - arsenazo III complex, and
absorbance values were recorded after 10–15 minutes at 652 nm.
Unknown concentrations of DTPA-ITC were calculated by using
a calibration plot and the following expression:
x~(y{0:11)={0:046
where x represents an unknown concentration of DTPA-ITC, and
y is the sample absorbance at 652 nm. After correction for protein
dilution, ligand to protein molar ratio was determined. These
experiments were done in triplicate.
Contrast Agent Preparation
Modifications of proteins with Gd-chelates are often performed
in two different buffers [41]. Protein chelation is often performed
in basic buffers, while metallation with gadolinium is performed in
acidic buffers.
Cages. Cage-DTPA-ITC nanoplatforms were prepared as
previously described. Finally, 0.9 equivalents of Gd-chloride (0.9:1
molar ratio Gd: DTPA-ITC) were added to a cage-DTPA-ITC
mixture (2.28 mg/ml of protein) in 20 mM MES buffer (pH 6.2).
After 2 hours, an aliquot was assayed for free Gd
3+ content using
Arsenazo III [44]. Briefly, a 10 mL sample is diluted into 1 ml of
20 mM arsenazo III and analyzed spectrophotometrically. The
mixture was then dialyzed against a 500-fold volume excess of
MES buffer (20 mM MES Na, pH 6.2, 2 mM DTT) for 12 hours
at 4uC, and protein concentration was determined by Bradford
protein assay (Bio-Rad, Hercules, CA).
Triskelia. To avoid modifying triskelia in acidic buffers, Gd-
chelates were prepared separately in ammonium acetate buffer
(pH 5.5). Acidic buffers are optimal for cages, but not for triskelia,
because triskelia can assemble into polyhedral cages at low pH
(,6.5) [45]. Based on spectrophotometric results, 81-fold molar
excess of DTPA-ITC (over the amount of triskelia) was solubilised
in 100 mM ammonium acetate and pH adjusted to pH 5.5 with
acetic acid. Then, 0.9 equivalents of gadolinium chloride were
added and reaction incubated at 37uC for 2 hours [46]. An aliquot
of gadolinium-DTPA-ITC was assayed for free gadolinium
content using arsenazo III [44]. Finally, clathrin triskelia in
concentration of about 5 mg/ml in 0.1 M HEPES buffer (pH 8.5)
were mixed with prepared Gd-DTPA-ITC for 8 hours at 4uC.
Unconjugated ligand was separated from the nanoplatforms by
dialysis (two times) against a 500-fold volume excess of phosphate
buffered saline (PBS) (pH 7.4) at 4uC for 24 hr. Protein
concentration was determined by Bradford protein assay (Bio-
Rad, Hercules, CA).
Figure 1. Structure of nanoplatforms. (A) The first diagram
represents a three-legged clathrin triskelion (light green). Transmission
electron microscopy (TEM) image shows clathrin triskelia with attached
Gd-DTPA-ITC negatively stained with 1% uranyl acetate. (B) The second
diagram represents clathrin cage lattice (blue) self-assembled from
clathrin triskelia. The TEM image shows clathrin cages with attached Gd-
DTPA-ITC negatively stained with 1% uranyl acetate. Clathrin cages
formed hexagonal barrels with D6 symmetry.
doi:10.1371/journal.pone.0035821.g001
Nanoplatforms for Magnetic Resonance Imaging
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e35821Figure 2. Size of nanoplatforms. Dynamic light scattering (DLS) measurements indicated the mean hydrodynamic radius of (A) clathrin triskelia
with Gd-DTPA contrast agents was 18.566.5 nm and of (B) fluorescent FITC-clathrin triskelia was 17.866.2 nm. The mean hydrodynamic radius of (C)
Gd-DTPA-clathrin cages was 55.1619.7 nm, and of (D) fluorescent rhodamine-PEG-clathrin cages was 71.6621.1 nm.
doi:10.1371/journal.pone.0035821.g002
Figure 3. Spectrophotometric method for the determination of a DTPA Ligand. (A) Linear relationship between the absorbance of the
yttrium complex of arsenazo III at 652 nm and the molarity of DTPA-ITC (R
2=0.999). (B) Relationship between the absorbance (A=652 nm) and the
concentration of DTPA-ITC during a sample titration of the yttrium complex of arsenazo III with DTPA-ITC-clathrin triskelia. The mean Ligand (DTPA-
ITC)/Protein (Clathrin Heavy Chain) molar ratio was 27.0464.8: 1. (C) The mean Ligand (DTPA-ITC)/Protein (Clathrin Heavy Chain) molar ratio was
4.261.04: 1 during a sample titration of the yttrium complex of arsenazo III with DTPA-ITC-clathrin cages.
doi:10.1371/journal.pone.0035821.g003
Nanoplatforms for Magnetic Resonance Imaging
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Gel analyses. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS–PAGE) was performed on a Mini-Protean
apparatus (Bio-Rad, Hercules, CA). Visualization of protein bands
was accomplished by Coomassie Brilliant Blue staining (Bio-Rad,
Hercules, CA). Commercially available standards (Bio-Rad,
Hercules, CA), and NIH ImageJ software (http://rsb.info.nih.
gov/ij) with MolWt macro (http://www.phase-hl.com/imagej.
htm) were used for the estimation of molecular weights.
Transmission Electron Microscopy (TEM). Analysis of
nanoparticle size and structure was performed on a Jeol 1200 EX
electron microscope (Jeol, Tokyo, Japan). About 5 mL of protein
solution (0.05 mg/ml) was applied to carbon-coated copper grids
for 3 minutes. The grids were rinsed with ddH2O, exposed to
5 mL of 1% solution of uranyl acetate (UA), and dried before
imaging.
Dynamic Light Scattering (DLS). DLS was performed
using a LB-550 (Horiba, Kyoto, Japan) to confirm size and
uniformity of nanoparticles.
T1 Relaxivity. In vitro relaxivity (r1) of Gadolinium-DTPA-
ITC-nanoparticles was established using a 0.47 T Bruker
Minispec NMR system (Bruker, Billerica, MA) at 40uC. The
longitudinal relaxation rate (R1=1/T1) was determined from 20
experimental time points generated by an inversion recovery pulse
sequence. Longitudinal relaxivity (r1) was calculated from the slope
of linear least squares fit of 1/T1 as a function of Gd
3+
concentration for different protein concentrations. Triskelia
nanoplatforms were in PBS buffer (pH 7.4), the relaxation rate
of the PBS buffer was (RPBS=0.2317), and protein concentration
was from 717.64 nmol/L to 5,741.16 nmol/L. Cage
nanoplatforms were in MES buffer (pH 6.2, RMES =0.2477),
and protein concentration was from 195.72 nmol/L to
1,565.77 nmol/L.
Mineralization monitored by relaxometry. The
gadolinium concentration of nanoparticle solutions was
measured by a relaxometric procedure according to the standard
method [47]. These experiments were performed in triplicate.
Briefly, a volume of 750 mL of each solution was added to 750 mL
of 70% HNO3 directly into a glass ampoule. After gentle
Figure 4. SDS-PAGE of the modified Clathrin nanoplatforms. (A) Clathrin triskelion Gd-contrast agent nanoplatform: Line 1. Standards; Line 2.
Unmodified Clathrin triskelia; Line 3. Clathrin triskelia with attached Gd-DTPA-ITC. SDS-PAGE analyses show that modified clathrin heavy chain (CHC)
bands in triskelia coincide with two molecular weight markers (190,988 kDa and 207, 532 kDa). Molecular weight of the triskelia CHCs increased by
10,143 and 26,687 Da. Thus, between 12.57 and 33.06 molecules of the Gd-DTPA-ITC were attached to the CHC. (B) Clathrin cage Gd-contrast agent
nanoplatform: Line 1. Standards; Line 2. Unmodified Clathrin cages; Line 3. Clathrin cages with attached Gd-DTPA-ITC. SDS-PAGE analyses show that
modified CHC bands in cages coincide with the molecular weight marker of 184,304 kDa. Molecular weight of the cage CHC increased by 3,794 Da,
indicating that 4.7 molecules of the Gd-DTPA-ITC were attached to each CHC. Abbreviations: T=triskelia, C=cages, TNP= triskelia nanoplatform,
CNP=cages nanoplatform.
doi:10.1371/journal.pone.0035821.g004
Nanoplatforms for Magnetic Resonance Imaging
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heated at 120uC for 5 days to ensure that all Gd
3+ was
solubilised as free aqua ion. Then the water proton T1 of these
solutions was measured at 20 MHz and 40uC, and Gd
3+
concentration in starting solutions determined from a standard
curve obtained using standard GdCl3 solutions (0.0125–0.4 mM),
and by using the following expression:
½Gd ~½(R 
1{R1B)

r1 |2
where r1 is the relaxivity (mM
21s
21) of the aqua ion under
identical standard experimental conditions, R1*( s
21) is the
relaxation rate of the sample, and R1B (s
21) is the relaxation
rate of the solution.
Fluorescent Studies
Brain distribution of clathrin-nanoparticles was assessed in rats
using fluorescent analysis of nanoparticles carrying fluorescein-
isothiocyanate (FITC, Pierce, Rockford, IL) and rhodamine-PEGs
(JenKem, Allen, TX) following intranasal, intraperitoneal, and
intravenous administration. FITC labels were conjugated to
triskelia using lysine residues [46]. Rhodamine-PEGs were
conjugated to clathrin cages using cysteine residues [48].
Florescent-tag to protein molar ratio was determined by
spectrophotometric and SDS-PAGE analyses. Dynamic light
scattering was performed using a LB-550 (Horiba, Kyoto, Japan)
to confirm size and uniformity of nanoparticles.
Male Sprague-Dawley (SD) rats (250 g–300 g) were anesthe-
tized with ketamine/xylazine (80/20 mg/kg). A volume of 70 mL
of clathrin nanoparticle PBS solution (33.3 mg of protein) was
delivered in nose drops (5 mL per drop) over a 30-minute period.
124 mg of protein in 250 mL of PBS was used for intravenous and
intraperitoneal administrations. Animals (n=4 per time point)
were sacrificed and perfused at 30, 60 and 90 minutes following
nanoparticle administration. Control animals (n=2) that did not
receive any nanoparticles were sacrificed and perfused before the
experiments. Animals were perfused transcardially with saline
followed by 4% paraformaldehyde. Brains were removed, post-
fixed and cryoprotected in three changes of 30% sucrose. Coronal
tissue sections (35 mm) were then cut throughout the entire brain
using a microtome. Sections were mounted, coverslipped, and
examined using a Zeis Axio Scope A1 photomicroscope (Zeiss,
Thornwood, NY).
Results
Structure of Nanoplatforms
Two different Gd-transporting nanoplatforms were developed.
The first utilized a clathrin triskelion (three-legged) protein
complex composed of a trimer of clathrin heavy chains (CHC),
each bound to a single clathrin light chain (CLC) (Fig.1A). The
second Gd-nanoplatform was based on a clathrin-cage self-
assembled from clathrin triskelia (Fig. 1B). Electron microscopy
showed a large proportion of conjugated Gd-DTPA-clathrin
triskelia (Fig. 1A), and also of conjugated Gd-DTPA-clathrin cages
(Fig.1B). The majority of Gd-DTPA-CCs had D6 symmetry,
formed hexagonal barrels, and had 36 clathrin triskelia, compris-
ing 108 heavy chains and 108 light chains.
Size of Nanoplatforms
The mean hydrodynamic radius of clathrin triskelia with
attached Gd-DTPA was 18.566.5 nm (Figure 2A). Previous
DLS studies of clathrin triskelia in solution also reported a Stokes
radius of 17 to 18 nm [49,50]. DLS instruments use spherical
models to estimate particle sizes. However, a triskelion is not a
spherical particle. A single triskelion has three legs that are bent,
puckered, and positioned differently in 3-dimensional space.
Electron microscopy has shown that triskelion legs can vary from
35 to 62 nm in total length after straightening [51,52]. High-
resolution atomic force microscopy also confirmed that the legs are
flexible along their entire length [53]. Thus, there is variability in
the measurements of triskelion size.
The mean hydrodynamic radius of Gd-DTPA-CCs was
55.1619.7 nm (Figure 2C), which is consistent with EM data for
clathrin barrels with D6 symmetry [45]. Thus, there is a slight
overlap in the sizes of triskelia and cages.
The mean hydrodynamic radius of FITC-clathrin triskelia was
17.866.2 nm (Figure 2B). Thus, FITC-triskelia were similar in
size to the GD-DTPA-labeled triskelia. The mean hydrodynamic
radius of the rhodamine-PEG-clathrin cages was 71.6621.1 nm
(Figure 2D). Rhodamine-PEG-cages were about 16 nm larger
than Gd-labeled cages, because rhodamine-PEGs (MW 3,867 Da,
JenKen Tech., Allen TX) were about 16 nm in size.
Chelate Ligand to Clathrin Protein Molar Ratio
A chelating agent (DTPA-ITC) was attached to clathrin protein,
and chelate to protein molar ratio (L/P) determined. Standard
spectrophotometric methods were used (Pippin et al. 1992 [43])
based on the reaction between DTPA-ITC ligand protein
conjugate and an yttrium (III) complex of arsenazo III.
Figure 3A shows dependence of absorbance at 652 nm on
DTPA-ITC molarity. Linearity of data demonstrates that Beer’s
law was observed over the concentration range of 022.0 mMo f
DTPA-ITC. Absorbance at 652 nm was determined for 20–80 ml
solutions of DTPA-ITC-Clathrin-triskelia (Fig. 3B) and DTPA-
ITC-Clathrin-cage conjugates (Fig. 3C). Protein concentration was
determined by Bradford protein assay. The mean DTPA-ITC:
Clathrin Heavy Chain molar ratio was 27.0464.8: 1 for triskelia,
and 4.261.04: 1 for cages.
SDS-PAGE image analyses showed the molecular weight of
modified clathrin heavy chain (CHC) in the triskelia-based
nanoplatform had changed from 184,845 to between
190,988 Da and 207,532 Da (Fig. 4A), whereas CHCs in the
CC-based nanoplatform had changed from 180,510 Da to
184,304 Da (Fig. 4B). These data are consistent with spectropho-
tometric data.
Rat CHC has 1675 amino acid residues, of which 97 are lysine
residues, but only some are available for conjugation with DTPA-
ITC. Molecular weight of the cage CHC increased by 3,794 Da,
indicating that 4.7 molecules of Gd-DTPA-ITC were attached to
each CHC.
After the modifications of CHC with GD-DTPA ITC in the
triskelia nanoplatform (TNP) we found 2 peaks that indicated
different molecular weights (190,988 Da and 207,532 Da). Thus,
molecular weight of triskelia CHCs increased by 10,143 Da (from
180,845 Da to 190,988 Da), and by 26,687 Da (from 180,845 Da
to 207,532 Da). Thus, between 12.57 and 33.06 molecules of Gd-
DTPA-ITC were attached to each CHC.
Fewer Gd-DTPA-ITC molecules were attached to CHCs in the
cage nanoplatform, because of a solubility problem. Cages that
averaged greater than 7 modifications per CHC were found to
easily precipitate, although diluting the sample could attenuate
precipitation. Ultimately, poor stability of these highly decorated
particles limited their characterization and subsequent Gd
3+
metallation, whereas cages with fewer DTPA-ITC molecules were
stable and not prone to aggregation.
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Gadolinium concentrations and T1 relaxivities were determined
for triskelia and cages. Gadolinium concentrations were measured
by relaxometry [47] and spectrophotometric methods [44].
Spectrophotometric results indicated that 100% of added
gadolinium was chelated by DTPA-ITC. The Gd to DTPA-ITC
molar ratio was 0.9:1. Nuclear Magnetic Resonance (NMR) results
confirmed spectrophotometric results for clathrin triskelia. The
Gd
3+ concentration in 750 ml of triskelia conjugate was
0.0689 mM according to spectrophotometric methods, and
0.0693 mM according to NMR methods. The Gd
3+ concentration
in 750 ml of cage conjugate was 0.0028 mM according to
spectrophotometric methods, and could not be detected by
NMR methods. Gd
3+ concentration in cage conjugate was below
the 0.01 mM detection limit of NMR [54,55].
Relaxivities for each sample were calculated using T1 data and
spectrophotometrically determined gadolinium concentrations. At
0.47 T, Gd-DTPA-ITC-triskelia displayed a relaxivity of
16 mM
21s
21per gadolinium ion (Fig. 5A) and 1,166 mM
21s
21per
particle. However, Gd-DTPA-ITC-cages displayed a relaxivity of
81 mM
21s
21 per gadolinium ion (Fig. 5B), and
31,512 mM
21s
21 per particle. Thus, triskelia exhibited 4 times
higher ionic relaxivity, and 291.5 times higher molecular relaxivity
compared to Gd-DTPA. Cages displayed 20 times higher
relaxivity per gadolinium ion than expected for a corresponding
amount of Gd-DTPA. Finally, clathrin cages had over 7,878-fold
greater molecular relaxivity than traditional Gd-MR contrast
agents, like gadopentetate dimeglumine. Diluted samples showed
slightly higher ionic relaxivities (22 mM
21s
21 for triskelia, and
97 mM
21s
21 for cages).
Fluorescent Clathrin Nanoplatforms In-Vivo
In order to determine whether clathrin nanoplatforms could
cross or bypass the BBB in rats, triskelia and cages were modified
with fluorescent tags. Fluorescent FITC labels were conjugated to
triskelia through reactive lysine residues using a Pierce FITC
Figure 5. T1 Relaxivity of the modified Clathrin nanoplatforms at 0.47 T. (A) Solid line (R
2=0.9996) represents a linear relationship between
the relaxivity rate of the modified clathrin triskelia and Gd molarity. Triskelia nanoplatforms had ionic relaxivity of 16 mM
21s
21. Molecular relaxivity
was 1,166 mM
21s
21.( B) Linear relationship (R
2=0.9977) between the relaxivity rate of the modified clathrin cages and the Gd molarity. Cages
nanoplatforms had ionic relaxivity of 81 mM
21s
21. Molecular relaxivity was 31,512 mM
21s
21.
doi:10.1371/journal.pone.0035821.g005
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were attached per triskelion complex, and the mean hydrody-
namic radius of FITC-clathrin triskelia was 17.866.2 nm (Fig. 2B).
Fluorescent triskelia-nanoparticles were administered intranasally
(i.n.) and intraperitoneally (i.p.) in male Sprague-Dawley (SD) rats
(250 g–300 g) at 30, 60, and 90 minutes time points. Ninety
minutes after i.n. and i.p. administration, FITC-labeled clathrin-
triskelia were identified in all rat brain regions examined, including
dopamine related areas (Figures 6, 7). Particles were also present in
brain regions 30 and 60 minutes post i.n. and i.p. administration.
Thus, clathrin triskelia successfully bypassed the BBB when
delivered intra-nasally, and/or crossed the BBB when delivered
intra-peritoneally, and were widely distributed throughout the
brain.
Next, rhodamine-PEGs were conjugated to clathrin cages
through reactive cysteine residues. 4.76 rhodamine-PEG molecules
were attached to each CHC of the cage, and the mean
hydrodynamic radius of the rhodamine-PEG-clathrin cages was
71.6621.1 nm (Fig. 2D). Nanoparticles were administered to rats
throughtheirtailveinsorintranasally.Rhodaminefluorescencewas
observed in all brain areas examined, including dopamine-rich
regions 90 minutes after i.v. and i.n. administration (Figures 6, 7).
Discussion
Two different Gd-nanoplatform methods were developed to
show feasibility of Clathrin protein-based imaging techniques. The
first method utilized a clathrin mono-unit (triskelion) with a radius
of 18.5 nm. This measure compares well with other DLS studies of
clathrin triskelion showing a Stokes radius of 17 to 18 nm [50]. An
individual triskelion consists of three 190 kDa (1,675-residue)
heavy chains, each bearing a single 25 kDa light chain [31]. A
triskelion has an apparent native ability to enter cells (e.g., neurons
[37]). Thus, triskelia nanoplatforms may offer significant potential
in support of imaging of intracellular molecular markers and cell
signaling pathways, for cellular tracking/imaging, and for
intracellular delivery of drugs, genes and/or antisense oligonucle-
otides.
The second method utilized a Gd-nanoplatform (size, 55.1 nm)
based on clathrin cages composed of self-assembled triskelia.
Triskelia legs create a lattice of hexagonal and pentagonal faces,
and cages exhibit a range of three-dimensional designs [42]. The
most frequently formed cage-like structures are built from 28, 36,
and 60 triskelia, which, respectively, are a ‘mini-coat’ with
tetrahedral symmetry, a ‘hexagonal barrel’ with D6 symmetry,
and a ‘soccer ball’ with icosahedral symmetry. Because of a
clathrin cage’s native ability to encapsulate and protect a wide
range of molecular structures (e.g., hormones, peptides, proteins,
antibodies, neurotransmitters) [30], cage nanoplatforms could be
utilized to deliver different ligands and/or drugs to specific sites of
action. Also, clathrin coats can be assembled on liposomes to form
clathrin-coated vesicles (CCV’s) [33]. Using vesicles could afford
another nano-transport cargo technique. Further, using free-
floating CA-complexes within assembled cages could present
another interesting target of opportunity [56].
The study goal was to create a method that would yield stable,
Gd-nanoplatforms that could provide enhanced CA imaging
performance. Chelate ligand (DTPA-ITC) was attached to
clathrin protein, and chelate to clathrin protein molar ratio was
determined by using standard spectrophotometric methods [43].
Figure 6. Delivery of Nanoplatforms across the Blood Brain Barrier to the anterior rat brain. Ninety minutes after (A) intranasal (IN) and
(B) intraperitoneal (IP) administration FITC-labeled clathrin-triskelia (green) were identified in all anterior brain regions including the corpus striatum
in rats. Also, rhodamine-PEG labeled clathrin cages (red) were identified in the striatum 90 minutes after (C) intranasal (IN) and (D) intravenous (IV)
delivery in rats. Images (E) and (F) of control (C) animals do not show any fluorescent patterns in the corpus striatum. The scale bar is 100 mm.
doi:10.1371/journal.pone.0035821.g006
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and 432 for a complete clathrin cage. Complete saturation of all
binding sites may result in a large number of metals attached to a
single nanoparticle complex, which is important for different
imaging and therapeutic modalities. However, clathrin cages with
a large number of chelating agents tended to precipitate, which is
consistent with some virus nanoparticle reports [57]. Encapsulat-
ing metal chelates, or attaching metal chelates to a clathrin cage’s
interior could prevent precipitation. Similar strategies have been
used with apoferritin [55], silicon particles [58] and viruses [57].
The smaller Gd-DTPA-ITC-triskelion platform displayed a
longitudinal relaxivity four times greater than that of the
monomeric chelate, and was similar to relaxivities reported for
some proteins (e.g., albumin, fibrinogen, IgG) [59], linear
polymers (e.g., poly-L-lysine) [60] and generation-5 dendrimers
[61] that were covalently bound to Gd-DTPA.
The cage-based CA nanoplatform displayed about 20-fold
greater ionic relaxivity than the monomeric chelate. In vitro
measurements of relaxivity at clinically relevant field strength
demonstrated additional gains from slow tumbling rates of
spherical clathrin cages. Observed ionic relaxivity is consistent
with relaxivity enhancement due to rotational correlation effects,
high local gadolinium concentrations, and relatively fast water
exchange inside a cage as reported in previous virus studies
[12,46,57,62]. However, nuclear magnetic resonance dispersion
(NMDR) studies need to be performed to further clarify relaxivity
issues.
Observed values were similar to values reported for apoferritin
[55]. Also, ionic relaxivities were higher than those reported for
other nanoparticles at 20 MHz [47] (Table 1). PAMAM
dendrimers (G=5, 7, 9, and 10) also display a high ionic relaxivity
(from 30 to 36 mM
21s
21) at 20 MHz [61]. Although the ionic
relaxivity did not increase, the total molecular relaxivities
increased (from 2,880 mM
21s
21 to 66,960 mM
21s
21) from
generation-5 to generation-10 dendrimers. Molecular relaxivity
was about 2 times higher in generation-10 dendrimers compared
to the clathrin cages. However, it may be possible to modify
Figure 7. Delivery of Nanoplatforms across the Blood Brain Barrier to the posterior rat brain. Ninety minutes after (A) intranasal (IN) and
(B) intraperitoneal (IP) administration FITC-labeled clathrin-triskelia (green) were identified in all posterior brain regions, including the substantia nigra
in rats. Also, rhodamine-PEG labeled clathrin cages (red) were identified in the substantia nigra 90 minutes after (C) intranasal (IN) and (D)
intravenous (IV) delivery in rats. Images (E) and (F) of control (C) animals do not show any fluorescent patterns in the substantia nigra. The scale bar is
100 mm.
doi:10.1371/journal.pone.0035821.g007
Table 1. MRI Nanoplatforms (at 20 MHz).
r1
(mM
21s
21) References
Gd-TREN-bis-HOPO-TAM-CO2H 7.3 Pierre et al. 2006 [70]
Clathrin triskelia-Gd-DTPA-ITC 16 This work
Gadomer 17 16.5 Nicolle et al. 2002 [71]
PAMAM-G4-Dendrimer-DOTA-Gd 31.2 Jaszberenyi et al. 2007 [72]
PAMAM-G10-Dendrimer-DOTA-Gd 36 Bryant et al. 1999 [61]
MS2-TREN-bis-HOPO-TAM 38.4 Datta et al. 2008 [47]
Apoferritin-HPDO3A 80 Aime et al. 2002 [55]
Clathrin cages-Gd-DTPA-ITC 81 This work
doi:10.1371/journal.pone.0035821.t001
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+3 ions inside
the protein cage to increase their molecular relaxivity.
Observed values were also lower than those reported for Gd
+3
ions attached to Calcium binding sites of wild-type or bioengi-
neered cowpea chlorotic mottle virus (CCMV) [202 mM
21s
21 at
61 MHz [63] and 210 mM
21s
21 respectively [62]]. However,
these sites bind Gd
3+ too weakly for clinical use. Also, endohedral
metallofullerenes [58,64] with a similar fullerene-like cage
structure to clathrin displayed a high ionic relaxivity (from
102 mM
21s
21 to 200 mM
21s
21). However, their toxicity is not
fully understood.
Some studies have focused on increasing molecular relaxivity
per particle by developing larger particles (over 100 nm in size)
that can carry a high payload of gadolinium CA. For example,
porous polymersomes (ca. 125 nm) encapsulated nearly 44,000
Gd
+3 per particle, and exhibited molecular relaxivity of
320,000 mM
21s
21 [65]. Also, paramagnetic liquid perfluorocar-
bon nanoparticles (ca. 250 nm) with over 90,000 Gd
3+ per particle
exhibited ionic relaxivity of 17.9 mM
21s
21, and molecular
relaxivity of 1,690,000 mM
21s
21 at 1.5T [9]. Thus, particles 2.5
to 5 times larger then clathrin cages demonstrated lower ionic
relaxivity, but showed higher molecular relaxivity because of a
higher number of gadolinium CA. However, particles over
100 nm in size have not been shown to cross the BBB [5].
Some studies have created clusters of nanoparticles to increase
their molecular relaxivity. For example, gadolinium-conjugated
dendrimer nanoclusters (DNCs) were prepared by crosslinking
fifth-generation PAMAM dendrimers with crosslinkers (e.g., NHS-
PEG-NHS) [66]. Paramagnetic DNCs were about 150 nm in
diameter, had an r1 relaxivity value of only 12.3 mM
21s
21 per
Gd
3+, but showed molecular relaxivity of approximately
3,600,000 mM
21s
21. Clathrin cages can also be crosslinked with
PEGs to form nanoclusters, which may increase their molecular
relaxivity, but may also limit their ability to cross the BBB [5].
To determine if these novel nanoplatforms could also enable in
vivo, noninvasive delivery into the CNS, fluorescent-tagged
triskelia and cages were designed, and utility for rat brain imaging
pilot-tested. These studies provide first evidence that fluorescent-
tagged clathrin nanoplatforms were successfully delivered non-
invasively into rat brain. Significantly, both triskelia and cages
crossed and/or bypassed the BBB without enhancers or
modifications, unlike other nanoparticle types [5]. One limitation
is that Gd-CA was not attached to the nanoplatforms. Also, the
mechanism of clathrin transport through the BBB is still unknown.
Prior studies showed [37] clathrin can be released by neurons and
move between them. Animal studies are currently conducted to:
clarify a mechanism of entry of clathrin nanoparticles into the
CNS; quantify nanoparticles in different organs and tissues;
evaluate if these nanoparticles with Gd-CA non-invasively enter
the CNS; and determine if they elicit CNS toxicity.
Thus, potent T1 Gd-DTPA contrast agents were created using
these novel nano-methods. However, a limitation was that
nanoparticle characterizations were performed at 20 MHz. It is
unclear whether similar relaxivities would be observed at other
field strengths. Lower relaxivities were found for T1 contrast
agents at higher fields [67,68]. Further studies are needed to find
optimal Gd-DTPA positioning (e.g., external vs. internal) and
loading for clathrin-nanoplatforms. Some studies showed longitu-
dinal relaxivities increased initially with increasing Gd-DTPA/
protein ratios, and reached a plateau at a particular Gd-DTPA/
protein ratio [69]. We reported T1 measures, but T2 measures
should also be performed and an r2/r1 ratio estimated. In general,
r1 should be as large as possible, and r2/r1 ratio should be as close
to 1 as possible in order for a nanoparticle to be used as a highly
sensitive T1 MRI contrast agent. In vitro experiments indicated
that a clathrin-based CA could produce as much contrast as
currently approved MRI contrast agents, but do so at much lower
concentrations, which is important for minimizing Gd-CA toxicity
in clinical applications. More important, the addition of ligands or
antibodies to the nanoplatform may provide the specificity needed
for molecular imaging. Further in-vivo MRI studies are required
to determine minimal MRI-visible concentration and test stability,
toxicity, biodistribution, and the general feasibility of these new
nanoplatforms for MR imaging. Finally, further in vivo studies will
show whether this novel nanoplatform can act as a potent, non-
invasive transporter into the CNS of Gd-CAs.
Conclusion
It was herein shown: 1) A new CA method utilizing Gd and
Clathrin bio-nanoparticles is feasible; 2) Clathrin protein proved a
robust nanoplatform onto which multiple functional motifs could
be added through chemical modifications of different amino acid
residues; 3) a single clathrin cage can carry hundreds of Gd
3+ ions
and has among the highest ionic relaxivity found for a Gd-DTPA
CA; 4) Clathrin nanoplatforms are size-adjustable (18 to 55 nm in
size); 5) clathrin cages are relatively stiff molecular structures with
large rotational correlation times, resulting in increased relaxivity
rates; and 6) fluorescent clathrin cages and triskelia can cross or
bypass the BBB without enhancers or modifications, and have
potential for non-invasive CNS imaging. These preliminary results
should encourage further investigation into this new nanoplatform
method for Gd-based imaging.
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